Clicky

Axsome Therapeutics, Inc.(AXSM) News

Date Title
Jul 30 2 Growth Stocks Wall Street Predicts Will Soar 74% to 159%
Jul 29 Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Jul 28 Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Jul 24 2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Jul 22 ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Jul 21 Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Jul 21 Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
Jun 11 Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley
Jun 11 Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
Jun 10 Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
Jun 9 Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
May 29 Axsome Therapeutics to Participate in Upcoming Investor Conferences
May 28 Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
May 27 Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
May 24 3 High-Flying Stocks That Could Soar Even More
Apr 10 Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy
Apr 8 Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
Mar 14 Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?
Feb 24 Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
Feb 24 Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs